We report here that systemic administration of DS2 decreases blood cytokine levels of, IL-6, TNF-α, and IL-17, three days post-stroke, which suggests that DS2-mediated suppression of innate immune cell activation could be associated with reduced numbers of Il-17 producing cells infiltrating the brain. Here, IL17A is linked to stroke disorder.